



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

19th September, 2016

To,

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Kind attention: Mr. Avishkar Naik

Dear Sirs,

Subject: Increase in Volume

We refer to your letter dated September 16, 2016 bearing Ref No. : NSE/CM/Surveillance/6456 seeking clarifications on the increase in the volume of securities of GlaxoSmithKline Pharmaceuticals Limited ("Company").

We wish to inform you there are no announcements that were pending and intimated to exchanges under Regulation 30 of the Listing Obligations and Disclosure requirements (LODR), Regulations, 2015. The Company is unaware of the reasons for the significant surge in volumes of our securities.

Further, we have ensured that investors have the latest and relevant information about our Company and going forward, all the necessary information concerning the Company including price sensitive information will be made available to the investors and Stock Exchanges based on the happening of the events.

We humbly request you to take the aforesaid reply on record and oblige.

We will glad to provide you any further clarification/information, if any required by you.

Yours faithfully
For GlaxoSmithKline Pharmaceuticals Limited



Authorized Signatory